The Dr. Oz hemp letter is one page on Centers for Medicare & Medicaid Services letterhead, addressed to “Honorable Members of the United States Senate,” and it asked them to kill an amendment that would have kept the federal hemp ban on schedule for November 12. It worked. About 36 hours later the Senate tabled that amendment 61-32. You can read the letter itself here.
The reason a Senate-confirmed health administrator was lobbying on hemp comes down to one number: $500.
What the Dr. Oz hemp letter actually argues
CMS Administrator Mehmet Oz’s pitch is not about recreational access. It is that CMS has already built hemp-derived CBD coverage into live payment models, and that killing the delay would gut them. Through the Center for Medicare and Medicaid Innovation, providers participating in the ACO REACH Model, the Enhancing Oncology Model and the Long-term Enhance ACO Design (LEAD) Model may cover up to $500 of hemp products annually per beneficiary, alongside expanded Medicare Advantage special supplemental benefits for the chronically ill.
“Passage of this amendment would undo significant gains that have been made to make clinically-appropriate full-spectrum hemp-derived CBD accessible to the senior citizens and individuals with disabilities that rely on the Medicare program for their healthcare,” Oz wrote. He asked senators to oppose the amendment, “which would rip away from millions of seniors and disabled Americans the opportunity to benefit from these new programs.”
And the closer: “Above all, we must ensure that our policies and procedures are not inhibiting access to items and services that are helping patients manage the agony caused by insidious diseases like cancer, debilitating seizure disorders, and other chronic pain.”
Do not oversell what Medicare actually covers
This is where coverage of the letter is going to go sideways, so let us be precise. This is not a Medicare entitlement. CBD is not a covered drug. What exists is optional flexibility for risk-bearing entities inside three CMMI demonstration models, plus supplemental benefits in Medicare Advantage, capped at $500 a year. A senior cannot walk into a pharmacy, hand over a Medicare card and get CBD. The program traces back to a December executive order on hemp-derived CBD research and an April launch.
Anti-legalization groups sued over the Medicare hemp coverage initiative. A federal judge granted the government’s motion to dismiss, and that dismissal is on appeal — so the legal ground under the program Oz is defending is not fully settled either.
The citation problem, and why it matters
Small detail with real consequences: the Oz letter targets “S. Amendment 6733 to H.R. 6500 as amended by S. Amendment 6732.” The Senate’s own roll call says the amendment tabled was 6747. Both numbers are in the public record. If you are citing this anywhere that matters, use 6747 — that is what the official vote page says was tabled. The posted letter also carries no date line.
The bigger point is institutional. An agency head lobbying the Senate on pending legislation that affects a program his own agency runs is not illegal. It is also not nothing. When people ask who the federal government’s hemp lobbyist is right now, the honest answer is: the Administrator of CMS. Meanwhile 35 attorneys general were writing the opposite letter, and they lost.
For operators, the practical takeaway is the same as always: watch what the payment rails do, not what Washington says. Square is cutting off CBD merchants on October 15 regardless of which date Congress lands on. See also our earlier coverage of the military marijuana ban after rescheduling.
Watch the full episode
We break this down on Cannabis Legalization News with Thomas Howard and Miggy 420.
Watch the full episode on YouTube.
